[go: up one dir, main page]

WO2019168222A1 - Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant - Google Patents

Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant Download PDF

Info

Publication number
WO2019168222A1
WO2019168222A1 PCT/KR2018/002504 KR2018002504W WO2019168222A1 WO 2019168222 A1 WO2019168222 A1 WO 2019168222A1 KR 2018002504 W KR2018002504 W KR 2018002504W WO 2019168222 A1 WO2019168222 A1 WO 2019168222A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
culture
peripheral blood
monoclonal antibody
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/002504
Other languages
English (en)
Korean (ko)
Inventor
강세찬
장선필
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genencell Co Ltd
Original Assignee
Genencell Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencell Co Ltd filed Critical Genencell Co Ltd
Priority to PCT/KR2018/002504 priority Critical patent/WO2019168222A1/fr
Publication of WO2019168222A1 publication Critical patent/WO2019168222A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Definitions

  • the present invention relates to a medium composition for culturing peripheral blood mononuclear cell-derived anti-cancer activated lymphocytes comprising a predetermined amount of interleukin-2 (IL-2), an anti-CD3 monoclonal antibody, an anti-CD16 monoclonal antibody, and a high blood normal hexane fraction, and an anticancer using the same. It relates to a method for culturing activated lymphocytes.
  • IL-2 interleukin-2
  • an anti-CD3 monoclonal antibody an anti-CD16 monoclonal antibody
  • a high blood normal hexane fraction a high blood normal hexane fraction
  • a surgical surgical treatment to remove a cancer-generating site As a means of treating cancer or a tumor, a surgical surgical treatment to remove a cancer-generating site, a chemotherapy to administer an anticancer agent, a radiation therapy to irradiate radiation to a cancer-generating site, and the like are common.
  • anti-cancer drugs are used to proliferate, select, or change the biological characteristics of cells in various ways by activating autologous, allogenic, or xenogenic cells in vitro and then activating anticancer activity to patients.
  • a fourth cancer treatment has been developed called immune cell therapy.
  • Representative anti-cancer immune cell therapies include self-activated lymphocyte therapy, such as lymphokine-activated killer (LAK) therapy or cytotoxic T lymphocyte (CTL) therapy.
  • LAK lymphokine-activated killer
  • CTL cytotoxic T lymphocyte
  • LAK therapy is a method of treating cancer of a patient by using the immunity of the patient's own lymphocytes proliferated and activated in vitro. Specifically, after (1) blood is collected from cancer patients, peripheral blood monocytes including lymphocytes are isolated, and (2) the isolated peripheral blood monocytes are separated from IL-2 (Interleukin-2) and anti-CD3 monoclonal antibodies. cultured in a medium containing (anti-CD3 monoclonal antibody) for 2 weeks to proliferate and activate lymphocytes, and (3) wash the cell suspension containing cultured lymphocytes to treat IL-2 and anti-CD3 antibodies. The medium is removed, the lymphocytes are suspended in an appropriate solution such as saline solution containing albumin, and prepared in the form of an injection.
  • IL-2 Interleukin-2
  • IL-2 Interleukin-2
  • anti-CD3 monoclonal antibody interleukin-2
  • the medium is removed, the lymphocytes are suspended in an appropriate solution such as saline solution containing albumin, and prepared
  • CTL therapy is a method of proliferating and activating cytotoxic T lymphocytes, and the treatment process is similar to that of LAK cell therapy.
  • various studies have been conducted to increase the specificity and effect of anticancer immune cell therapy.
  • Cinnabar bark is the bark or root bark of the mulberry tree ( Meliaazedarach L. var. Japonica Makino ), and is native to Korea, China, and Japan. It is known to have antiparasitic, insecticidal, antimalarial, contraceptive, and antibacterial effects, and is used for the treatment of formal medicine, worms, and malaria fever. It has been reported that ethanol extract of Rhizobarium inhibits iNOS and that beta-carboline alkaloids exhibit anti-inflammatory activity by inhibiting iNOS in Raw264.7 cell line. In addition, the present inventors have reported the anti-cancer activity effect of the extract of Gyunpi in Korean Patent No. 10-1609935 through animal experiments, Gyunpi normal hexane fraction shows little cytotoxicity, when co-administration with anticancer agent It has been reported to show the characteristic efficacy of anticancer synergistic effect and anticancer drug side effects.
  • the use of the bark normal hexane fraction itself as an anticancer agent is disclosed, but for the culture method in which the bark normal hexane fraction promotes the differentiation into NK cells, NKT cells, and T cells, which are immune cells that have anticancer activity, and proliferates them. It has not been disclosed at all.
  • Korean Patent No. 10-1039843 relates to a medium composition for culturing self-activated lymphocytes and a method for culturing self-activated lymphocytes using the same, which promotes differentiation of immune cells into NK cells, NKT cells, and T cells and lacks mass proliferation.
  • the anticancer effect of killing tumor cells to inhibit proliferation is not high.
  • Patent Document 1 Korean Registered Patent No. 10-1609935
  • Patent Document 2 Korean Registered Patent No. 10-1039843
  • the present inventors conducted a study to find a culture composition that is superior to a known medium for activating lymphocyte culture medium, as a result of the study, the high blood normal hexane fraction with little cytotoxicity and interleukin-2 (IL-2), anti
  • IL-2 interleukin-2
  • -CD3 monoclonal antibody and anti-CD16 monoclonal antibody are used as an additive for a predetermined amount of cell culture medium, it was found that the differentiation into NK cells, NKT cells and T cells, which are immune cells, can be greatly promoted and proliferated.
  • the present invention has been completed. Furthermore, it was confirmed that the immune cells proliferated by the method of the present invention significantly inhibited the cell proliferation of cancer cells, and the anticancer power was greatly enhanced in comparison with the existing LAK cells in animal tests (see Experimental Example).
  • an object of the present invention is to provide a medium composition for culturing natural killer cells (NK Cell), natural killer T cells (NKT Cell), and peripheral blood mononuclear cell-derived anti-cancer activated lymphocytes capable of effectively proliferating T cells.
  • Another object of the present invention is to provide a method for culturing peripheral blood monocyte-derived anti-cancer activated lymphocytes using the medium composition.
  • Another object of the present invention is to provide a pharmaceutical composition for treating cancer comprising peripheral blood mononuclear cell-derived anti-cancer activated lymphocytes cultured by the culture method.
  • the present invention is a medium composition for mass culturing anti-cancer activated lymphocytes comprising a cell culture medium and an additive added to the cell culture medium, wherein the additive is interleukin-2 (IL- 2), anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody, and provides a medium composition for culturing peripheral blood mononuclear cell derived anti-cancer activated lymphocytes, characterized in that it comprises a normal blood hexane fraction.
  • IL-2 interleukin-2
  • IL-2 interleukin-2
  • anti-CD3 monoclonal antibody anti-CD16 monoclonal antibody
  • the present invention comprises the steps of separating peripheral blood monocytes into peripheral blood; Putting the isolated peripheral blood mononuclear cells into the cell culture medium and culturing in the presence of interleukin-2 (IL-2), anti-CD16 monoclonal antibody, and the bark normal hexane fraction; A second culture step of obtaining cells from the culture medium in which the culture was completed in the first culture step, and culturing the obtained cells in the presence of interleukin-2 (IL-2), anti-CD3 monoclonal antibody, and pulmonary normal hexane fraction; And obtaining cells from the culture medium in the second culture step, and culturing the obtained cells in the presence of interleukin-2 (IL-2), anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody, and the bark normal hexane fraction. It provides a peripheral blood mononuclear cell-derived anti-cancer activated lymphocyte culture method comprising a third culture step.
  • IL-2 interleukin-2
  • IL-2 inter
  • the present invention also provides a pharmaceutical composition for treating cancer comprising peripheral blood mononuclear cell-derived anticancer activated lymphocytes cultured by the above method.
  • the culture composition provided by the present invention comprises a fraction of high-fidelity normal hexane, thereby significantly differentiating and proliferating into NK cells, NKT cells, and T cells, which are immune cells that have anticancer activity, compared to conventional lymphokine-activated killer (LAK) cells.
  • LAK lymphokine-activated killer
  • the media composition of the present invention can be used as an anticancer treatment by itself, it can greatly enhance the anticancer power while alleviating side effects by lowering the dose of the existing anticancer agent when used in combination in the clinic as a chemical anticancer agent.
  • Example 1 is a graph comparing the number of immune cells proliferated using a conventional culture method (Comparative Example 1) and a culture method using the activated lymphocyte culture medium composition according to the present invention (Example 1).
  • 2A-2C are diagrams illustrating the differentiation and phenotypic changes of lymphocytes using flow cytometry.
  • Figures 3a-3c is a result of measuring the viability of the cells using the 51 Cr release assay.
  • Figure 4 is a result confirming the cancer cell proliferation inhibitory effect using a lung cancer model animal.
  • the present invention relates to a medium composition for mass culturing anti-cancer activated lymphocytes comprising a cell culture medium and an additive added to the cell culture medium.
  • the additive is interleukin-2 (IL-2), anti -CD3 monoclonal antibody, anti-CD16 monoclonal antibody, and cinnabar normal hexane fraction.
  • the anti-cancer activated lymphocytes in the present invention mean natural killer cells (NK Cell), natural killer T cells (NKT Cell), and T cells.
  • the NK cells are large granular lymphocytes (LGL), a characteristic type of lymphocytes, and their antitumor activity occurs in necrosis, apoptosis, or both mechanisms. It is done by NK cells respond to cytokines such as IL-2, IL-12, Interferon, and the like, thereby raising cytotoxicity, secretory, and proliferative functions. Phenotypes of NK cells are CD16 (Fc ⁇ RIII) and CD56 in humans, and CD16 and CD56 do not have a T-cell receptor complex (TRC) on the cell surface and thus are used as markers for NK cells.
  • TRC T-cell receptor complex
  • T cells refer to cells having an T cell receptor (TCR) on the cell surface.
  • TCR forms a heterodimer with the CD3 antigen of the di- and ⁇ -chain dimers. Some of the T cells (around 5% of peripheral blood T cells) are dimers of ⁇ and ⁇ chains, not ⁇ .
  • TCR forms a complex with the CD3 antigen ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ or ⁇ ), which plays a role in delivering the signal into the cell when TCR recognizes the antigen.
  • NKT cells are a type of T cell whose function is being revealed relatively recently as an attendant of endogenous immunity. As the name suggests, it expresses T-cell receptors and NK cell-specific surface markers.
  • One surprising feature of NKT cells is the rapid release of several cytokines such as IL-4, IL-10, IL-13, IFN- ⁇ , TNF- ⁇ after activation. This feature suggests that NKT cells can have a significant effect on the adaptive immune response.
  • interleukin-2 is a glycoprotein (glycoprotein) having a molecular weight of 14 to 17 kDa that is produced when T cells recognize and activate an antigen, is secreted out of T cells, and then IL-2. It reacts with the T cells themselves, which promotes the growth of the corresponding T cells. IL-2 also acts on NK cells to promote growth, enhances NK cell killing capacity, and acts on B cells to promote their growth.
  • IL-2 is a glycoprotein (glycoprotein) having a molecular weight of 14 to 17 kDa that is produced when T cells recognize and activate an antigen, is secreted out of T cells, and then IL-2. It reacts with the T cells themselves, which promotes the growth of the corresponding T cells. IL-2 also acts on NK cells to promote growth, enhances NK cell killing capacity, and acts on B cells to promote their growth.
  • CD16 antigen When lymphocytes are cultured in the presence of anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody or antigen antibody complex, CD16 antigen is added to NK cells and signaling occurs. Transferrin receptors such as ⁇ chains, or tumor necrosis factor (TNF) or IFN- ⁇ can be produced.
  • TNF tumor necrosis factor
  • IL-2 anti-CD3 monoclonal antibody and anti-CD16 monoclonal antibody were used as a medium additive in culture.
  • IL-2 was used for proliferation of T cells and NK cells, and each monoantibody was used.
  • CD16 in immune cells in the present invention further comprises a high blood normal hexane fraction, NK cells, T cells and NKT cells to proliferate and activate significantly.
  • the bark normal hexane fraction greatly promotes differentiation and proliferation into NK cells, T cells and NKT cells.
  • the medium composition of the present invention is a cell culture medium that can be used in conventional cell culture, and interleukin-2 (IL-2) 100 ⁇ 200000 IU / ml as an additive; Anti-CD3 monoclonal antibody 10-100000 ng / ml; Anti-CD16 monoclonal antibody 10-100000 ng / ml; And 25-250 ⁇ g / ml of the bark normal hexane fraction.
  • IL-2 interleukin-2
  • the present invention provides a peripheral blood mononuclear cell-derived anti-cancer activated lymphocyte culture method using the culture composition.
  • separating peripheral blood monocytes with peripheral blood Putting the isolated peripheral blood mononuclear cells into the cell culture medium and culturing in the presence of interleukin-2 (IL-2), anti-CD16 monoclonal antibody, and the bark normal hexane fraction; A second culture step of obtaining cells from the culture medium in which the culture was completed in the first culture step, and culturing the obtained cells in the presence of interleukin-2 (IL-2), anti-CD3 monoclonal antibody, and pulmonary normal hexane fraction; And obtaining cells from the culture medium in the second culture step, and culturing the obtained cells in the presence of interleukin-2 (IL-2), anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody, and the bark normal hexane fraction.
  • IL-2 interleukin-2
  • IL-2 interleukin-2
  • peripheral blood mononuclear cells refer to monocytes (Mononuclear Cell) isolated from peripheral blood (Peripheral Blood) commonly used for anticancer immunotherapy.
  • Peripheral blood monocytes can be separated from blood by centrifugation using specific gravity, and the degree and composition of immune cells is confirmed by flow cytometry.
  • the peripheral blood monocytes may be obtained from a patient or cancer patient having a normal risk of cancer.
  • the peripheral blood mononuclear cells used in the present invention are not necessarily self-derived, and if the peripheral blood mononuclear cells derived from the same species can be used for the induction and proliferation of natural killer cells for anticancer immune treatment according to the present invention.
  • the peripheral blood mononuclear cells isolated in the cell culture medium are put and cultured in the presence of Interleukin-2 (IL-2), anti-CD16 monoclonal antibody, and the pulmonary blood normal hexane fraction.
  • IL-2 Interleukin-2
  • anti-CD16 monoclonal antibody anti-CD16 monoclonal antibody
  • the cell culture medium may further include a nutrient component or a pH adjuster for culturing peripheral blood mononuclear cells.
  • a medium containing such a component RPMI-1640, DMEM, serum-free medium, and the like may be used, and reagents commonly used in cell culture may be included. Examples of such reagents include serum (human or fetal), albumin, antibiotics and antifungal agents, L-glutamine, sodium pyruvate, transferrin, insulin and the like.
  • the culture medium containing the additive IL-2, anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody and the hexane fraction can be prepared by the following method.
  • the culture medium is prepared by adding IL-2, anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody, and bark hexane fraction to the cell culture medium, or a medium containing anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody. It can also be prepared by coating each antibody in a flask in advance, and adding the remaining culture component to the flask.
  • the cell culture medium during the first to the third culture step the concentration of IL-2 100 ⁇ 200000 IU / ml, anti-CD3 Concentrations of monoclonal antibodies of 10 to 100000 ng / ml and concentrations of anti-CD16 monoclonal antibodies of 10 to 100000 ng / ml, and bark normal hexane fractions can be used within the range of 25 to 250 ⁇ g / ml. The amount of these may be adjusted and used within the above range through each culture step, but is not necessarily limited.
  • interleukin-2 200-1000 IU / ml
  • anti-CD16 monoclonal antibody 1000-30000 ng / ml
  • the bark normal hexane fraction 30-75 ⁇ g / ml
  • the culture conditions of the first culture step are not particularly limited, and conditions used in normal cell culture can be used. In one embodiment, it is preferable to incubate at a temperature of 30 ⁇ 38 °C and a condition of CO 2 concentration of 5 to 10%. The culture period is 3 to 5 days in order to activate and proliferate peripheral blood monocytes, and to fully differentiate and proliferate into NK cells, NKT cells and the like, and may be longer. In addition, culture medium exchange can be appropriately carried out during the culture.
  • the culture is performed under conditions that selectively differentiate peripheral blood monocytes into cytotoxic T cells, and the peripheral blood monocytes, which have not been stimulated in the first culture step, are selectively differentiated and expanded into T cells.
  • NK cells and NKT cells differentiated, activated and proliferated in the first culture stage can be stimulated, directly or indirectly, by T cells activated in the second culture stage to significantly activate and proliferate NK cells and NKT cells. .
  • the second culture step in order to selectively differentiate peripheral blood monocytes into cytotoxic T cells, cells are obtained from the culture medium cultured in the first culture step, and the obtained cells are interleukin-2 (IL-2), Incubated in the presence of anti-CD3 monoclonal antibody, and a barley normal hexane fraction.
  • IL-2 interleukin-2
  • the cell culture medium during the first to third culture stages has a concentration of 100-20000 IU / ml of IL-2, a concentration of 10-100000 ng / ml of anti-CD3 monoclonal antibody, and an anti-CD16 monoclonal antibody.
  • concentration of 10 to 100000 ng / ml, the concentration of the bark normal hexane fraction can be used within the range of 25 ⁇ 250 ⁇ g / ml.
  • the second culture step uses 200-1000 IU / ml of interleukin-2 (IL-2), 1000-30000 ng / ml of anti-CD3 monoclonal antibody, and 30-75 [mu] g / ml of the bark normal hexane fraction.
  • IL-2 interleukin-2
  • IL-2 interleukin-2
  • anti-CD3 monoclonal antibody 10-75 [mu] g / ml of the bark normal hexane fraction.
  • the culture solution is exchanged at the start of the second culture step to perform the culture.
  • the culture conditions of the second culture step is not particularly limited, and may be cultured under the same conditions as specified in the first culture step, and the culture period is sufficient for the differentiation and proliferation of peripheral blood monocytes into cytotoxic T cells. It can be 3 to 5 days or more.
  • culture medium exchange can be appropriately carried out during the culture.
  • the third culture step is a step of additionally culturing the cells obtained in the culture medium of the second culture step in a culture medium containing IL-2, anti-CD16 monoclonal antibody, anti-CD3 monoclonal antibody and the bark hexane fraction.
  • the third culture step may further activate and proliferate the immune cells differentiated and expanded in the first and second culture steps.
  • cells are obtained from the culture medium in the second culture step, and the obtained cells are interleukin-2 (IL-2), anti-CD3 monoclonal antibody, anti-CD16 monoclonal antibody, and cinnabar rind. Incubate in the presence of normal hexane fractions.
  • IL-2 interleukin-2
  • anti-CD3 monoclonal antibody anti-CD3 monoclonal antibody
  • anti-CD16 monoclonal antibody anti-CD16 monoclonal antibody
  • cinnabar rind cinnabar rind
  • the cell culture medium undergoes a concentration of 100-20000 IU / ml of IL-2, a concentration of 10-100000 ng / ml of anti-CD3 monoclonal antibody, and an anti-CD16 monoclonal antibody during the first to third culture steps.
  • concentration of 10 to 100000 ng / ml, the concentration of the bark normal hexane fraction can be used within the range of 25 ⁇ 250 ⁇ g / ml.
  • interleukin-2 200 to 1000 IU / ml
  • anti-CD3 monoclonal antibody 1000 to 30000 ng / ml anti-CD16 monoclonal antibody 1000 to 30000 ng / ml
  • high blood normal Hexane fractions 30-75 ⁇ g / ml are used.
  • the culture medium is exchanged at the start of the third culture step to perform the culture.
  • the culture conditions of the third culture step is not particularly limited, can be cultured under the same conditions as specified in the first and second culture step, the culture period is 3 to 5 in order for the immune cells to fully differentiate and proliferate I can do it more than a day.
  • culture medium exchange can be appropriately carried out during the culture.
  • peripheral blood of 30 ml was collected, and peripheral blood mononuclear cells were separated from blood by centrifugation and selected as experimental groups (peripheral blood mononuclear cells).
  • the peripheral blood mononuclear cells thus separated were added to 50 ml of a medium containing IL-2 (Interleukin-2) 200 IU / ml and anti-CD3 monoclonal antibody 10000 ng / ml, and cultured for 2 weeks, thereby proliferating and activating lymphocyte cells.
  • IL-2 Interleukin-2
  • peripheral blood of 30 ml was collected, and peripheral blood mononuclear cells were separated from blood by centrifugation and selected as experimental groups (peripheral blood mononuclear cells).
  • peripheral blood monocytes were suspended in 50 ml of medium to which 200 IU / ml of IL-2 and 50 ⁇ g / ml of the bark normal hexane fraction obtained in Preparation Example 1 were added, and 10000 ng / ml of anti-CD16 monoclonal antibody.
  • a 75 cm 2 flask coated with a 37 ° C 5% CO 2 conditions were incubated for 5 days using a cell incubator (first culture step).
  • the cells were recovered from the flask at the end of the first culture step (Day 5), and the recovered cells were again added with 200 IU / mL of IL-2 and 50 ⁇ g / mL of the bark normal hexane fraction. Suspended in ml medium (primary culture medium), and then placed in a sterile gas permeable cell culture medium coated with anti-CD3 monoclonal antibody 10000 ng / ml for 4 days at 37 °C, 5% CO 2 conditions using a cell incubator The culture was carried out (second culture step).
  • the cells were recovered from the flask at the end of the second culture step (Day 9), and the recovered cells were again subjected to 200 IU / ml of IL-2, 10000 ng / ml anti-CD3 monoclonal antibody, 10000 ng / ml.
  • IL-2 10000 ng / ml anti-CD3 monoclonal antibody
  • 10000 ng / ml anti-CD3 monoclonal antibody
  • the cells were incubated at 37 ° C. and 5% CO 2 for 4 days using a cell culture medium. 3 culture steps).
  • Comparative Example 1 and Example 1 obtained through the above culture process were compared with the total lymphocyte cell numbers including NK cells, NKT cells, and T cells, and are shown in FIG. 1.
  • the number of cells before the culture was 2.0x10 6 ⁇ 1.3x10 7, but by the conventional LAK cell culture method (Comparative Example 1) was 2.3x10 9 ⁇ 3.70x10 9 or more, according to the present invention By culture method (Example 1), it was confirmed that the growth was 3.1x10 9 ⁇ 4.8x10 9 or more.
  • the lymphocytes prepared by the culturing method according to the present invention had an increase in cell number of about 35% or more compared with the lymphocytes prepared by the conventional LAK cell culture method.
  • the activated lymphocytes cultured in Comparative Example 1 and Example 1 were analyzed for surface antigen of each immune cell using flow cytometry, and the results are shown in FIG.
  • the H1 region shows T cells
  • the H2 region shows NKT cells
  • the H4 region shows NK cells
  • the H3 region shows the distribution of other immune cells.
  • the surface antigen distribution is most distributed in the H4 region before the cultivation, whereas the distribution of the H1 and H2 regions is obtained after the culturing by the culturing method (Example 1) according to the present invention. Was found to be increased.
  • the lymphocytes produced by the culture method according to the present invention is increased in differentiation and activity compared to the lymphocytes produced by the conventional LAK cell culture method.
  • the activated lymphocytes cultured in Comparative Examples 1 and 1 were confirmed the secretion level of IFN- ⁇ by ELISPOT assay, and CD69 expression, which is an active surface antigen of lymphocytes, was measured by flow cytometry. b) and (c).
  • the lymphocytes prepared by the culture method according to the present invention is IFN- ⁇ compared to lymphocytes prepared by the conventional LAK cell culture method (Comparative Example 1) Increased secretion and expression of CD69 was found to increase the activity was confirmed.
  • the immune cell-containing compositions prepared in Comparative Example 1 and Example 1 were placed in a 15 ml centrifuge tube, centrifuged (1400 rpm, 5 minutes), and the supernatant was removed to separate cells.
  • apoptosis effects on the human lung cancer cell line A549, the human liver cancer cell line HepG2, and the human cervical cancer cell line SiHa were confirmed using a 51 Cr release assay, and the results are shown in FIG. 3.
  • the cell death effect was calculated based on Equation 1 below.
  • % Apoptosis ((experimental release-spontaneous release) / (maximal release-spontaneous release)) ⁇ 100
  • Example 1 As shown in Figure 3, it was confirmed that the lymphocytes prepared by the culture method according to the present invention (Example 1) has a higher killing effect on cancer cells than lymphocytes prepared by the conventional LAK cell culture method (Comparative Example 1). .
  • the immune cell-containing compositions prepared in Comparative Example 1 and Example 1 were placed in a 15 ml centrifuge tube, centrifuged (1400 rpm, 5 minutes), and the supernatant was removed to separate cells.
  • the isolated immune cells were administered intravenously to BALB / c nude mice in which tumors were formed by administering A549, a non-small cell lung cancer line, to confirm the effect of inhibiting tumor growth.
  • Example 1 As shown in Figure 4, it was confirmed that the lymphocytes prepared by the culture method according to the present invention (Example 1) showed a higher tumor growth inhibitory effect than lymphocytes prepared by the conventional LAK cell culture method (Comparative Example 1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une composition de milieu de culture pour la culture de lymphocytes activés anticancéreux dérivés de cellules mononucléaires du sang périphérique et un procédé de culture de lymphocytes activés anticancéreux l'utilisant. Plus spécifiquement, lorsque la composition contient une fraction d'hexane normale de Melia azedarach L., l'interleukine-2 (IL -2), l'anticorps monoclonal anti-CD3 et l'anticorps monoclonal anti-CD16, les effets de différenciation activée et de prolifération en masse des cellules NK, des cellules NKT et des cellules T (correspondant aux lymphocytes activés anticancéreux) à partir de cellules mononucléaires du sang périphérique ont été confirmés. En conséquence, la présente invention concerne une composition de culture basée sur une fraction d'hexane normale de Melia azedarach L. et un procédé de culture de cellules mononucléaires du sang périphérique l'utilisant. En outre, les lymphocytes activés anticancéreux dérivés de cellules mononucléaires du sang périphérique cultivées par le procédé selon la présente invention peuvent être utilisés en tant que composition pharmaceutique qui est hautement efficace pour le traitement du cancer. En outre, la composition de milieu de culture de la présente invention peut elle-même être utilisée en tant que traitement anticancéreux, et lorsqu'un médicament anticancéreux chimique est administré en combinaison dans une utilisation clinique, le dosage d'un médicament anticancéreux existant peut être abaissé, ce qui permet d'atténuer les effets secondaires et d'améliorer considérablement l'activité anticancéreuse.
PCT/KR2018/002504 2018-02-28 2018-02-28 Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant Ceased WO2019168222A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2018/002504 WO2019168222A1 (fr) 2018-02-28 2018-02-28 Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2018/002504 WO2019168222A1 (fr) 2018-02-28 2018-02-28 Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant

Publications (1)

Publication Number Publication Date
WO2019168222A1 true WO2019168222A1 (fr) 2019-09-06

Family

ID=67805048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/002504 Ceased WO2019168222A1 (fr) 2018-02-28 2018-02-28 Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant

Country Status (1)

Country Link
WO (1) WO2019168222A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066644B2 (en) 2018-02-01 2021-07-20 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN115247150A (zh) * 2021-12-17 2022-10-28 黑龙江诺亚康大干细胞技术有限责任公司 一种nk细胞的培养及冻存方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090127974A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
KR20120017502A (ko) * 2010-08-19 2012-02-29 인제대학교 산학협력단 참죽 추출물을 함유하는 항암용 조성물
KR20140021882A (ko) * 2012-08-13 2014-02-21 주식회사 알엔에스 에이엠피케이 활성화 효과를 가지는 조성물
KR20140132975A (ko) * 2013-05-09 2014-11-19 (주)비타바이오 고련피 추출물을 포함하는 선천면역 증강 및 항바이러스 조성물
KR20160006814A (ko) * 2014-07-09 2016-01-20 가천대학교 산학협력단 고련피 노르말헥산 분획물을 포함하는 항암 보조용 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090127974A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
KR20120017502A (ko) * 2010-08-19 2012-02-29 인제대학교 산학협력단 참죽 추출물을 함유하는 항암용 조성물
KR20140021882A (ko) * 2012-08-13 2014-02-21 주식회사 알엔에스 에이엠피케이 활성화 효과를 가지는 조성물
KR20140132975A (ko) * 2013-05-09 2014-11-19 (주)비타바이오 고련피 추출물을 포함하는 선천면역 증강 및 항바이러스 조성물
KR20160006814A (ko) * 2014-07-09 2016-01-20 가천대학교 산학협력단 고련피 노르말헥산 분획물을 포함하는 항암 보조용 약학적 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066644B2 (en) 2018-02-01 2021-07-20 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US12098388B2 (en) 2018-02-01 2024-09-24 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN115247150A (zh) * 2021-12-17 2022-10-28 黑龙江诺亚康大干细胞技术有限责任公司 一种nk细胞的培养及冻存方法

Similar Documents

Publication Publication Date Title
WO2012030057A2 (fr) Composition de milieu pour cultiver des lymphocytes auto-activés et procédé de culture de lymphocytes auto-activés l'utilisant
JP6869994B2 (ja) Ｎｋ細胞培養用培地添加キット、及びキットを用いるｎｋ細胞培養方法
WO2016209021A1 (fr) Méthode pour faire proliférer des cellules tueuses naturelles et composition pour faire proliférer des cellules tueuses naturelles
KR102236011B1 (ko) Nk 세포의 대량증식 배양방법
KR20090127974A (ko) 자기활성화 림프구 배양용 배지 조성물
KR20090127973A (ko) 자기활성화 림프구 배양 방법
KR20200132722A (ko) 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트
KR101867942B1 (ko) 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법
WO2020231200A1 (fr) Procédé efficace de culture de cellules tueuses naturelles, et kit à ajout de milieu associé
WO2019117633A1 (fr) Composition cosmétique et composition pharmaceutique pour atténuer la dermatite atopique, la chute des cheveux et les plaies ou réduire les rides de la peau
WO2019198995A1 (fr) Procédé de conversion à base d'exosomes pour cellules immunitaires
WO2017188790A1 (fr) Procédé de mise en prolifération et de culture de cellules immunitaires dans des conditions hypoxiques
WO2022045813A1 (fr) Composition pharmaceutique pour le traitement, la prévention ou l'inhibition des métastases d'un cancer du poumon, comprenant un exosome en tant que principe actif
WO2019168222A1 (fr) Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant
WO2019103436A9 (fr) Composition pour la culture de cellules nk et procédé pour la culture de cellules nk l'utilisant
WO2015076430A1 (fr) Composition pour la prévention ou le traitement de maladies immunes, contenant de la metformine en tant que principe actif
CN116904400B (zh) 可利霉素在体外car/tcr-t细胞产品制备过程优化中的应用
WO2024090703A1 (fr) Procédé de culture efficace pour la prolifération de cellules tueuses naturelles et son utilisation
KR102765799B1 (ko) Cd56+ 자연살해세포를 포함하는 항암용 조성물
KR101432881B1 (ko) 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물
KR101839413B1 (ko) 말초혈액단핵구 유래 항암 활성화 림프구 배양용 배지 조성물 및 이를 이용한 항암 활성화 림프구 배양방법
KR101273747B1 (ko) Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
CN115925974A (zh) 一种针对实体瘤的通用性的ips来源的car-nk细胞的制备方法
WO2024071671A1 (fr) Nouveau procédé de culture double pour la culture de cellules immunitaires et de cellules tueuses naturelles, et son utilisation
KR101177273B1 (ko) 췌도세포의 배양시 그의 생존률 또는 기능을 증진시키는방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18908059

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18908059

Country of ref document: EP

Kind code of ref document: A1